General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Us2.ai(SIGNIFICANT), Alleviant Medical(MODEST), Allysta Pharma(MODEST), AnaCardio(MODEST), Applied Therapeutics(MODEST), AstraZeneca Pharmaceuticals(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Boston Scientific (SIGNIFICANT), Cytokinetics(MODEST), Darma Inc(NONE), Eli Lilly(SIGNIFICANT), Impulse Dynamics(MODEST), Ionis Pharma(MODEST), Janssen Research & Development(SIGNIFICANT), Medscape/WebMD(SIGNIFICANT), Merck & Co., Inc.(MODEST), Novartis(SIGNIFICANT), Novo Nordisk(SIGNIFICANT), Radcliffe(MODEST), Biopeutics(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), EchoNous Inc(NONE), Intellia Therapeutics(MODEST), Prosciento Inc(NONE), Recardio(NONE), ReCor Medical(NONE), Roche(NONE), Sanofi(NONE), Siemens Healthcare (NONE), Bristol Myers Squibb (NONE), CardioRenal (NONE), Quidel Corporation (MODEST) RESEARCH/RESEARCH GRANTS: Clinician Scientist Award (National Medical Research Council of Singapore)(SIGNIFICANT), Roche(SIGNIFICANT), Novo Nordisk (SIGNIFICANT) OTHER FINANCIAL BENEFIT: Us2.ai(SIGNIFICANT), Us2.ai(NONE)

View Full Disclosure